Cardiac rhythm device surgery with uninterrupted oral anticoagulation
- PMID: 24180532
- DOI: 10.2217/fca.13.80
Cardiac rhythm device surgery with uninterrupted oral anticoagulation
Abstract
Current guidelines recommend interrupting anticoagulation and bridging therapy with heparin or low-molecular-weight heparin for cardiac rhythm device surgeries in patients with high thrombotic risk. However, there are some studies that suggest continuing warfarin may be safe. The study by Birnie et al. investigates this important clinical question in a randomized controlled trial setting. They randomly assigned 681 patients with high thrombotic risk (5% or more per year), in 18 centers, to receive either stopping warfarin combined with heparin bridging (standard of care) or continued uninterrupted warfarin therapy for cardiac rhythm device surgery. The trial was terminated after a second prespecified interim analysis by the data and safety monitoring board. Clinically significant device-pocket hematoma was noted in 12 out of 343 patients (3.5%) in the uninterrupted warfarin group, compared with 54 out of 338 (16.0%) in the heparin-bridging group (relative risk: 0.19; 95% CI: 0.10-0.36; p < 0.001). Uninterrupted warfarin was associated with better patient satisfaction, and there was no significant difference in thromboembolic or surgical complications between the two groups. These results demonstrate that device surgeries can be safely performed with continued warfarin, and bridging with heparin is associated with high risk of device-pocket hematoma.
Comment on
-
Pacemaker or defibrillator surgery without interruption of anticoagulation.N Engl J Med. 2013 May 30;368(22):2084-93. doi: 10.1056/NEJMoa1302946. Epub 2013 May 9. N Engl J Med. 2013. PMID: 23659733 Clinical Trial.
Similar articles
-
Pacemaker or defibrillator surgery without interruption of anticoagulation.N Engl J Med. 2013 May 30;368(22):2084-93. doi: 10.1056/NEJMoa1302946. Epub 2013 May 9. N Engl J Med. 2013. PMID: 23659733 Clinical Trial.
-
Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies.Eur Rev Med Pharmacol Sci. 2015 Apr;19(8):1461-79. Eur Rev Med Pharmacol Sci. 2015. PMID: 25967723 Review.
-
Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation.Heart Rhythm. 2010 Jun;7(6):745-9. doi: 10.1016/j.hrthm.2010.02.018. Epub 2010 Feb 20. Heart Rhythm. 2010. PMID: 20176137
-
Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial.Europace. 2017 Oct 1;19(10):1630-1636. doi: 10.1093/europace/euw409. Europace. 2017. PMID: 28339794 Clinical Trial.
-
Management of Perioperative Anticoagulation for Device Implantation.Card Electrophysiol Clin. 2018 Mar;10(1):99-109. doi: 10.1016/j.ccep.2017.11.008. Card Electrophysiol Clin. 2018. PMID: 29428146 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical